CA2609733C - 6,7-unsaturated-7-carbamoyl-substituted morphinan derivative - Google Patents

6,7-unsaturated-7-carbamoyl-substituted morphinan derivative Download PDF

Info

Publication number
CA2609733C
CA2609733C CA2609733A CA2609733A CA2609733C CA 2609733 C CA2609733 C CA 2609733C CA 2609733 A CA2609733 A CA 2609733A CA 2609733 A CA2609733 A CA 2609733A CA 2609733 C CA2609733 C CA 2609733C
Authority
CA
Canada
Prior art keywords
optionally substituted
compound
chiral
lower alkyl
pharmaceutically acceptable
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CA2609733A
Other languages
English (en)
French (fr)
Other versions
CA2609733A1 (en
Inventor
Masanao Inagaki
Shin-Ichiro Hara
Nobuhiro Haga
Yoshinori Tamura
Yoshihisa Goto
Tsuyoshi Hasegawa
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Shionogi and Co Ltd
Original Assignee
Shionogi and Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Shionogi and Co Ltd filed Critical Shionogi and Co Ltd
Publication of CA2609733A1 publication Critical patent/CA2609733A1/en
Application granted granted Critical
Publication of CA2609733C publication Critical patent/CA2609733C/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D489/00—Heterocyclic compounds containing 4aH-8, 9 c- Iminoethano-phenanthro [4, 5-b, c, d] furan ring systems, e.g. derivatives of [4, 5-epoxy]-morphinan of the formula:
    • C07D489/06—Heterocyclic compounds containing 4aH-8, 9 c- Iminoethano-phenanthro [4, 5-b, c, d] furan ring systems, e.g. derivatives of [4, 5-epoxy]-morphinan of the formula: with a hetero atom directly attached in position 14
    • C07D489/08—Oxygen atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/485—Morphinan derivatives, e.g. morphine, codeine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/10—Laxatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biomedical Technology (AREA)
  • Pain & Pain Management (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Hospice & Palliative Care (AREA)
  • Otolaryngology (AREA)
  • Emergency Medicine (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
CA2609733A 2005-05-25 2006-05-25 6,7-unsaturated-7-carbamoyl-substituted morphinan derivative Active CA2609733C (en)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
JP2005151864 2005-05-25
JP2005-151864 2005-05-25
JP2006065762 2006-03-10
JP2006-065762 2006-03-10
PCT/JP2006/310231 WO2006126529A1 (ja) 2005-05-25 2006-05-23 ６，７－不飽和－７－カルバモイル置換モルヒナン誘導体
JPPCT/JP2006/310231 2006-05-23
PCT/JP2006/310454 WO2006126637A1 (ja) 2005-05-25 2006-05-25 ６，７－不飽和－７－カルバモイル置換モルヒナン誘導体

Publications (2)

Publication Number Publication Date
CA2609733A1 CA2609733A1 (en) 2006-11-30
CA2609733C true CA2609733C (en) 2011-07-19

Family

ID=37451954

Family Applications (1)

Application Number Title Priority Date Filing Date
CA2609733A Active CA2609733C (en) 2005-05-25 2006-05-25 6,7-unsaturated-7-carbamoyl-substituted morphinan derivative

Country Status (20)

Country Link
US (4) US8084460B2 (https=)
EP (1) EP1889848B8 (https=)
JP (1) JP4323547B2 (https=)
KR (1) KR100912782B1 (https=)
CN (1) CN101228172B (https=)
AU (1) AU2006250390B2 (https=)
BE (1) BE2019C533I2 (https=)
BR (1) BRPI0610343B8 (https=)
CA (1) CA2609733C (https=)
DK (1) DK1889848T3 (https=)
ES (1) ES2525215T3 (https=)
FR (1) FR19C1042I2 (https=)
HU (1) HUS1900034I1 (https=)
MX (1) MX2007014588A (https=)
NL (1) NL300996I2 (https=)
PL (1) PL1889848T3 (https=)
PT (1) PT1889848E (https=)
RU (1) RU2403255C2 (https=)
TW (1) TWI311056B (https=)
WO (2) WO2006126529A1 (https=)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2006126529A1 (ja) 2005-05-25 2006-11-30 Shionogi & Co., Ltd. ６，７－不飽和－７－カルバモイル置換モルヒナン誘導体
US8173666B2 (en) 2007-03-12 2012-05-08 Nektar Therapeutics Oligomer-opioid agonist conjugates
US10512644B2 (en) 2007-03-12 2019-12-24 Inheris Pharmaceuticals, Inc. Oligomer-opioid agonist conjugates
ES2620672T3 (es) * 2008-01-09 2017-06-29 Charleston Laboratories, Inc. Comprimidos de doble capa que comprenden oxicodona y prometazina
JP5252391B2 (ja) * 2008-02-21 2013-07-31 学校法人北里研究所 オキサビシクロ［２．２．２］オクタンを有するモルヒナン誘導体およびその医薬用途
KR101660996B1 (ko) * 2008-09-16 2016-09-28 넥타르 테라퓨틱스 남용에 대한 낮은 잠재성을 갖는 페길화 오피오이드
AU2010295464B2 (en) * 2009-09-18 2015-11-26 Merck Sharp & Dohme Corp. Use of opioid receptor antagonist for gastrointestinal tract disorders
US20130217672A1 (en) * 2010-05-13 2013-08-22 Green Cross Corporation (+)-3-hydroxymorphinan-based polycycle derivatives
RU2607084C2 (ru) * 2010-11-12 2017-01-10 Сионоги Энд Ко., Лтд. Кристаллы производных 6,7-ненасыщенного-7-карбамоилморфинана и способ их получения
WO2013172297A1 (ja) 2012-05-14 2013-11-21 塩野義製薬株式会社 ６，７－不飽和－７－カルバモイルモルヒナン誘導体含有製剤
EP3560487A4 (en) 2016-12-26 2020-07-29 Shionogi & Co., Ltd. PRODUCTION METHOD FOR FORMULATION WITH IMPROVED UNIFORMITY OF CONTENT
JP7365358B2 (ja) 2018-04-12 2023-10-19 モーフィック セラピューティック，インコーポレイテッド ヒトインテグリンα４β７のアンタゴニスト
KR102201609B1 (ko) 2019-04-19 2021-01-12 연성정밀화학(주) 날데메딘의 제조방법
WO2021076890A1 (en) 2019-10-16 2021-04-22 Morphic Therapeutic, Inc. INHIBITING HUMAN INTEGRIN α4β7
JP7582961B2 (ja) 2019-11-20 2024-11-13 塩野義製薬株式会社 ６，７－不飽和－７－カルバモイルモルヒナン誘導体含有固形製剤
CN111905111B (zh) * 2020-09-16 2023-03-31 地奥集团成都药业股份有限公司 一种评价复方谷氨酰胺组方对腹泻型肠易激综合征疗效的方法
IT202300009864A1 (it) * 2023-05-16 2024-11-16 Procos Spa Processo per la preparazione di naldemedina
CN121534059A (zh) * 2024-08-09 2026-02-17 盐野义有限公司 一种治疗帕金森综合征或帕金森病的方法和药物组合物

Family Cites Families (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4272541A (en) 1978-06-02 1981-06-09 Miles Laboratories, Inc. 7,8 and 7-8 Substituted 4,5α-epoxymorphinan-6-one compounds, and methods of treating pain and drug dependence with them
US4275205A (en) * 1980-05-05 1981-06-23 Miles Laboratories, Inc. 7,7-Ditosyloxymethyl-4,5α-epoxy-morphinan-6-ols
US4347361A (en) * 1980-12-10 1982-08-31 Sisa, Incorporated 4,5α-Epoxy-3-hydroxy or methoxy-7-(1-hydroxy-alkyl or 1-oxoalkyl)morphinan-6-one compounds
US4370333A (en) 1981-06-29 1983-01-25 Sisa, Incorporated 17-Cyclopropylmethyl-3-hydroxy-14-methoxy 7α-methyl-morphinan-6-one and therapeutic method of treating pain with it
US4443605A (en) * 1982-07-30 1984-04-17 Miles Laboratories, Inc. 7β-Arylalkyl-6α, 7 α-oxymethylene-3-methoxy or 3-hydroxy-4, 5α-epoxy-17 methyl or 17-cycloalkyl-methyl morphinans
US4440932A (en) * 1982-09-09 1984-04-03 Miles Laboratories, Inc. 7β-Arylalkyl-7α-methyl-6-oxo or 6α-hydroxy-3-methoxy or 3-hydroxy-4,5α-epoxy-17-methyl or 17-cycloalkyl-methylmorphinans
US4668685A (en) * 1984-07-05 1987-05-26 E.I. Du Pont De Nemours And Company Substituted benzoate ester prodrug derivatives of 3-hydroxymorphinans, which are analgesics or narcotic antagonists
AU686203B2 (en) * 1993-07-23 1998-02-05 Toray Industries, Inc. Morphinan derivative and medicinal use
US5464841A (en) 1993-11-08 1995-11-07 Univ Minnesota Use of delta opioid receptor antagonists to treat immunoregulatory disorders
ATE229958T1 (de) 1996-01-10 2003-01-15 Glaxosmithkline Spa Heterocyclische kondensierte morphin-derivate
WO2001002375A1 (en) 1999-07-01 2001-01-11 Chemrx Advanced Technologies, Inc. Process for synthesizing oxadiazoles
US6451806B2 (en) * 1999-09-29 2002-09-17 Adolor Corporation Methods and compositions involving opioids and antagonists thereof
NZ518562A (en) * 1999-11-29 2005-04-29 Adolor Corp Novel methods and compositions involving opioids and antagonists thereof
WO2001085150A2 (en) 2000-05-05 2001-11-15 Pain Therapeutics, Inc. Opioid antagonist containing composition for enchaching the potency or reducing adverse side effects ofopioid agonists
EP1284736A2 (en) 2000-05-05 2003-02-26 Pain Therapeutics, Inc. Opioid antagonist compositions and dosage forms
US20040024004A1 (en) 2001-05-04 2004-02-05 Sherman Barry M. Novel compositions and methods for enhancing potency or reducing adverse side effects of opioid agonists
AU2002227135B2 (en) * 2000-10-31 2008-01-03 Rensselaer Polytechnic Institute 8- substituted-2, 6-methano-3-benzazocines and 3-substituted morphinanes as opioid receptor binding agents
AU2408602A (en) * 2000-11-22 2002-06-03 Toray Industries Indole derivatives and use thereof in medicines
HUP0401600A3 (en) * 2001-08-23 2008-05-28 Organon Nv Process for the preparation of 14-hydroxymorphine derivatives
DE10161963A1 (de) * 2001-12-17 2003-07-03 Johannes Schuetz 6-Aminomorphinanderivate, Herstellungsverfahren dafür und deren Verwendung
DE10229842A1 (de) * 2002-07-03 2004-02-05 Helmut Prof. Dr. Schmidhammer Morphinanderivate und deren quartäre Ammoniumsalze substituiert in Position 14, Herstellungsverfahren und Verwendung
US20060052409A1 (en) * 2002-07-11 2006-03-09 Koji Kawai Therapeutic or preventive agent for nausea/vomiting
CA2498046A1 (en) * 2002-09-18 2004-04-01 The Curators Of The University Of Missouri Opiate analogs selective for the delta-opioid receptor
US20040157784A1 (en) 2003-02-10 2004-08-12 Jame Fine Chemicals, Inc. Opiod tannate compositions
WO2005105093A2 (en) 2003-08-26 2005-11-10 Duke University METHOD OF ARRESTING THE SIDE EFFECTS OF µ-OPIOID RECEPTOR AGONISTS DURING THEIR ADMINISTRATION
JP5266492B2 (ja) 2004-05-28 2013-08-21 ヒューマン バイオモレキュラル リサーチ インスティテュート 代謝安定性鎮痛薬、疼痛薬物療法及び他の物質の合成
US20060063792A1 (en) 2004-09-17 2006-03-23 Adolor Corporation Substituted morphinans and methods of their use
US7142420B2 (en) 2004-09-20 2006-11-28 Qualcomm, Incorporated Devices and methods for controlling relative movement between layers of an electronic device
WO2006126529A1 (ja) 2005-05-25 2006-11-30 Shionogi & Co., Ltd. ６，７－不飽和－７－カルバモイル置換モルヒナン誘導体
RU2607084C2 (ru) 2010-11-12 2017-01-10 Сионоги Энд Ко., Лтд. Кристаллы производных 6,7-ненасыщенного-7-карбамоилморфинана и способ их получения

Also Published As

Publication number Publication date
BRPI0610343A2 (pt) 2010-06-15
US20120135978A1 (en) 2012-05-31
TWI311056B (en) 2009-06-21
US20090203723A1 (en) 2009-08-13
EP1889848B8 (en) 2014-12-17
JPWO2006126637A1 (ja) 2008-12-25
ES2525215T3 (es) 2014-12-19
CN101228172B (zh) 2013-04-03
CA2609733A1 (en) 2006-11-30
CN101228172A (zh) 2008-07-23
KR100912782B1 (ko) 2009-08-18
PL1889848T3 (pl) 2015-04-30
AU2006250390A1 (en) 2006-11-30
FR19C1042I1 (https=) 2019-08-09
EP1889848A1 (en) 2008-02-20
EP1889848A4 (en) 2011-08-10
US8084460B2 (en) 2011-12-27
EP1889848B1 (en) 2014-10-15
NL300996I1 (nl) 2019-07-03
TW200726470A (en) 2007-07-16
BE2019C533I2 (https=) 2025-12-10
DK1889848T3 (en) 2014-12-01
PT1889848E (pt) 2014-12-09
JP4323547B2 (ja) 2009-09-02
KR20080014791A (ko) 2008-02-14
HUS1900034I1 (hu) 2019-07-29
MX2007014588A (es) 2008-01-24
US8536192B2 (en) 2013-09-17
RU2403255C2 (ru) 2010-11-10
FR19C1042I2 (fr) 2020-06-19
WO2006126637A1 (ja) 2006-11-30
BRPI0610343B8 (pt) 2021-05-25
RU2007148412A (ru) 2009-06-27
AU2006250390B2 (en) 2010-07-08
USRE46365E1 (en) 2017-04-11
WO2006126529A1 (ja) 2006-11-30
NL300996I2 (nl) 2019-07-30
USRE46375E1 (en) 2017-04-25
BRPI0610343B1 (pt) 2020-03-10

Similar Documents

Publication Publication Date Title
CA2609733C (en) 6,7-unsaturated-7-carbamoyl-substituted morphinan derivative
DE69321525T2 (de) Morphinan-derivate und medizinische verwendung
US6187782B1 (en) Morphinane derivatives and medicinal use thereof
CA2861150C (en) Morphinan derivative
TWI723511B (zh) 一種高活性sting蛋白激動劑化合物
WO1995003308A1 (fr) Derive de morphinane et application medicale
JPWO1995003308A1 (ja) モルヒナン誘導体および医薬用途
EP3019503A1 (en) Polycyclic-carbamoylpyridone compounds and their use for the treatment of hiv infections
KR20170016957A (ko) 폴리엔 마크로라이드 유도체
CN115043836A (zh) 一种咪唑并吡啶衍生物的p2x3受体选择性调节剂及其药物用途
US9963460B1 (en) Morphinan derivative
WO2022218311A1 (en) Modulators of bcl-2 or bcl-2/bcl-xl and uses thereof
HK40121692A (zh) 一种tdg抑制剂化合物及其用途
TW202608878A (zh) Ｎｌｒｐ３炎症小體抑制劑及其用途
NO et al. 3rd Phase, Bangalore 560078 (IN).
CZ2000459A3 (cs) Krystalický 10,10-bis(2-fluor-4- pyridinyl)methyl)-9(10H)-anthracenon a zlepšený způsob jeho přípravy

Legal Events

Date Code Title Description
EEER Examination request
MPN Maintenance fee for patent paid

Free format text: FEE DESCRIPTION TEXT: MF (PATENT, 19TH ANNIV.) - STANDARD

Year of fee payment: 19

U00 Fee paid

Free format text: ST27 STATUS EVENT CODE: A-4-4-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED

Effective date: 20250402

U11 Full renewal or maintenance fee paid

Free format text: ST27 STATUS EVENT CODE: A-4-4-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL

Effective date: 20250402